South Africa-based Aspen Pharmacare has agreed to sell the commercialization rights and intellectual property of its European women’s health business to pharmaceutical and medical device company Ennogen for $220 million.
Through the deal, Ennogen will acquire the supply and manufacturing rights for Ovestin, an estriol-based menopause hormone therapy used to treat menopause-related symptoms, along with approximately $4.4 million in existing inventory.
The acquisition will expand Ennogen’s European footprint and topical product portfolio. Aspen will retain its European manufacturing partnerships and continue providing facilitation services for Ovestin for at least five years.
